Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)
May 11, 2023 11:58 ET
|
Smart Immune
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA) Two poster presentations at EHA showcase ProTcell, an innovative...
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform
April 17, 2023 01:00 ET
|
Smart Immune
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform The new funding from the Gates Foundation will advance a Phase 1/2 clinical trial of an...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
March 30, 2023 07:00 ET
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
March 30, 2023 04:24 ET
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune is selected for the first cohort of the French Tech Health20 program
March 27, 2023 07:32 ET
|
Smart Immune
Smart Immune is selected for the first cohort of the French Tech Health20 program This unique program has selected 20 French start-ups that offer disruptive healthcare innovations PARIS, France,...
Smart Immune appoints world-class Clinical Advisory Board
November 21, 2022 07:00 ET
|
Smart Immune
Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
October 13, 2022 07:00 ET
|
Smart Immune
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers First trial...
Smart Immune Bolsters Management Team with Medical and Technical Appointments
September 13, 2022 07:00 ET
|
Smart Immune
Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...
Smart Immune appoints world-leading experts to its Scientific Advisory Board
July 28, 2022 07:00 ET
|
Smart Immune
Smart Immune appoints world-leading expertsto its Scientific Advisory Board PARIS, France, July 28, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a...
Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board
July 06, 2022 07:25 ET
|
Smart Immune
Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board PARIS, France, July 6, 2022 – Smart Immune SAS, a clinical-stage biotechnology...